Property | Value |
?:abstract
|
-
SARS-CoV-2 infection of human airway epithelium activates genetic programs that lead to progressive hyperinflammation in COVID-19 patients. Here we report on the transcriptomic response of airway epithelium to interferons and its suppression by the JAK inhibitors Baricitinib and Ruxolitinib. There is a debate on the regulation of the conventional versus the novel intronic promoter inducing the short ACE2 isoform. Through RNA-seq and ChIP-seq analyses for activating chromatin marks and Polymerase II, we define the interferon-activated intronic regulatory region. Our results also support that the conventional ACE2 promoter is controlled by interferon.
|
?:creator
|
|
?:doi
|
-
10.1101/2020.10.04.325415
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/04ba6746f480d4ae60d74487de05fb2f0c0381dc.json; document_parses/pdf_json/bd5cd329fcd8b5772cc53158a9eecfd6ef112366.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7553184.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
-
BioRxiv; Medline; PMC; WHO
|
?:title
|
-
Activation of ACE2 and interferon-stimulated transcriptomes in human airway epithelium is curbed by Janus Kinase inhibitors
|
?:type
|
|
?:year
|
|